Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
May 28th 2024The expert panel underscores the critical importance of rapid diagnostic testing and identification of driver alterations to optimize patient outcomes, given the often-narrow therapeutic window for chemotherapy and targeted therapies.
NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
May 28th 2024Key opinion leaders examine the current National Comprehensive Cancer Network (NCCN) guidelines regarding the utilization of liquid and tissue biopsies, highlighting the necessity for the NCCN to prioritize and recommend concurrent testing as the preferred approach over relying on a single liquid or tissue biopsy alone.
Concurrent NSCLC Biomarker Testing at Diagnosis
May 21st 2024Martin Dietrich, MD, PhD, shares his approach to optimizing the use of diagnostic testing from both a tissue perspective and cost perspective, noting he routinely orders tissue and liquid biopsies during the initial patient visit if prior testing has not been conducted.
Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
May 21st 2024Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, emphasize the crucial role of molecular testing in disease diagnosis, focusing on the significance of rapid turnaround times and the ability of liquid biopsies to address time-sensitive diagnostic needs.
UNICORN Study: Osimertinib and Other Emerging Treatments for Uncommon EGFR Mutations
December 27th 2023Insights into how the UNICORN study, which assessed osimertinib, is impacting treatment decisions for uncommon EGFR mutations, and other ongoing trials shedding light on effective treatments for this patient population.
Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC
December 20th 2023Expert insights on sequencing treatment options for patients with uncommon EGFR mutations who have progressed on afatinib, emphasizing clinical trial considerations, biomarker testing, and emerging therapeutic approaches.
Zanubrutinib Triplet Shows Early Promise in Treatment-Naive TP53-Mutant MCL
December 11th 2023The combination comprised of zanubrutinib, obinutuzumab, and venetoclax elicited high response rates and 2-year progression-free survival rates that compared favorably with historical outcomes achieved with chemoimmunotherapy in high-risk patients with previously untreated mantle cell lymphoma harboring TP53 mutations.
Dr Monk on the Investigation of B7-H4–Directed Vedotin ADCs in Gynecologic Cancers
December 7th 2023Bradley Monk, MD, FACS, FACOG, discusses the rationale for investigating B7-H4–directed vedotin antibody-drug conjugates and highlights how these agents may address unmet needs for patients with gynecologic cancers.
Providing Timely Cancer Care Access Is Crucial Amid Growing Patient Volume
A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.
Ontada®, a McKesson business dedicated to leveraging oncology real-world data and evidence, clinical education, and provider technology, was awarded a competitive contract with the U.S. Food and Drug Administration to advance the use of real-world data in the U.S. community oncology setting.
Physicians Must Become Advocates to Play a Role in Community Oncology’s Future
September 25th 2023Although some community oncologists may think they can do little to abate the reimbursement reform forces that are affecting their practices, there are actions they can, and should, take to influence the success of their value-based care journey that may not be part of the fundamentals of their current practice.